Keywords: Human Genome, GlaxoSmithKline, Benlysta, Seattle Genetics, Ligand, Genentech, Roche
Human Genome/GlaxoSmithKline lupus drug Benlysta disappoints in Ph III; Updates on Seattle Genetics and Ligand milestones
Article | 21 April 2010
USA-based Human Genome Sciences and UK drug giant GlaxoSmithKline yesterday revealed top-line secondary endpoints from BLISS-76, the second of two ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
